São Paulo, SP – October 1, 2025 – Novo Nordisk and Eurofarma today announce a strategic partnership to expand the national reach of biological injectable semaglutide in Brazil. The agreement aims to strengthen the distribution and promotion of the molecule, including specialties, pharmacies, and regions currently not served by Novo Nordisk.

Under the signed agreement, Eurofarma — a pharmaceutical multinational of Brazilian origin present in 24 countries and one of the leaders in the Latin American market — will be the exclusive distributor for the marketing and promotion of two new high-quality weekly injectable semaglutide brands in the Brazilian market: Poviztra®, indicated for the treatment of obesity and overweight with associated comorbidities, and Extensior®, focused on the treatment of type 2 diabetes.

The initiative integrates the ongoing efforts of both companies to broaden the reach of these excellent, safe, and effective therapies. By joining forces with an ethical partner and a leader in medical prescriptions in Brazil, Novo Nordisk reinforces its pioneering role in the treatment of chronic diseases.

"Novo Nordisk is proud to lead innovation in GLP-1 therapies and to transform lives with medicines like Wegovy® and Ozempic®. This partnership is a strategic step to ensure that our innovation reaches even more people throughout Brazil, with the same trust and quality as always," says Allan Finkel, Vice President of Novo Nordisk Latam and Brazil.

"Eurofarma brings the experience and capacity of its sales force to expand the reach of these products, within a project that contemplates a strong commitment to doctors and patients, scientific excellence, innovation, and robust local execution capacity," highlights Renata Campos, CEO of Eurofarma Brazil.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, based on our heritage in diabetes treatment. We do this through scientific innovation, expanding access to our medicines, and continuous work to prevent and eventually cure diseases. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in approximately 170 countries. Present in Brazil since 1990, the company currently has about 2,500 employees and is present with a corporate office in São Paulo (SP) and a production unit in Montes Claros (MG). For more information, visit www.novonordisk.com.br and follow our official profiles on the social networks Instagram, Facebook, LinkedIn, and YouTube.

About Eurofarma
Founded in 1972, Eurofarma operates in the healthcare sector, producing and marketing products and services to improve people's quality of life. Focused on shared value generation, it covers key pharmaceutical segments such as medical prescription, generics, hospital, oncology, over-the-counter medicines, personal care, and animal health, in addition to providing production services to third parties. With broad coverage across therapeutic classes, the portfolio comprises more than 4,000 SKUs, serving practically all medical specialties. Leader in medical prescription in Brazil, where it also holds the vice-leadership in generics, Eurofarma is present in 24 countries, with 100% coverage in Latin America and leadership in the region's retail market. It also maintains operations in the USA and Africa, with a total of more than 13.5 thousand employees and 11 factories, and accounted for 600 million units produced in 2024. In the same year, the company invested more than R$ 800 million in innovation projects and achieved net revenue exceeding R$ 11 billion.

Eurofarma Press Office
G&A Relações Públicas
e-mail: imprensaeurofarma@gaspar.com.br 
Iza França - +55 11 97644-4496 
Guilherme Gaspar - +55 11 98285-6000